LOS ANGELES- Red Light Holland Corp., has announced significant advancements in their natural psilocybin microdosing capsules. Developed from psilocybin truffles grown on the company’s farm in the Netherlands, these capsules have successfully passed a four-month stability test, confirming the stability of psilocybin.
This recent accomplishment builds on the company’s prior achievements, including the completion of a Certificate Of Analysis, which verified that Red Light Holland’s capsules are of medical grade quality, free from pesticides, biocontaminants, or heavy metals. Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is focused on providing premium psilocybin truffles to legal, recreational markets in the Netherlands, adhering to all applicable laws.
The stability tests, conducted by C-Crest Laboratories Inc., a Montreal-based cGMP pharmaceutical laboratory, have been a pivotal step in Red Light Holland’s mission to create medical-grade homogenized natural psilocybin microdosing capsules. The tests, which were conducted over four months, aimed to determine the shelf life of the capsules and confirmed the maintenance of psychoactive compounds – psilocybin and psilocin.
These capsules are slated for distribution in Australia and New Zealand through NUBU Pharmaceuticals, a leading medical cannabis company. With the latest results and the upcoming official reports from C-Crest, NUBU Pharmaceuticals will be able to apply for an import license.
Todd Shapiro, CEO and Director of Red Light Holland, expressed pride in these developments, noting the company’s pioneering role in passing rigorous tests and its plan to produce and sell lab-tested and approved homogenized microdosing capsules. Shapiro highlighted a recent report from the Canadian Senate Subcommittee for Veterans Affairs, recommending an expansion of psychedelic therapy for veterans and noted the potential role of Red Light Holland’s tested capsules in providing a safe product for such therapies.
Shapiro also acknowledged the importance of Remembrance Day and the company’s alignment with efforts to support research on psychedelic-assisted therapy for Canadian veterans suffering from PTSD and related conditions.
Alex Grenier, CEO of Shaman Pharma and President of C-Crest Laboratories, commended the robust results for the microdosing capsules, emphasizing their stable shelf life and the significance of this milestone in developing high-quality natural psilocybin products. Red Light Holland’s ongoing strides in the field are seen as a crucial part of broader efforts to assist individuals in need, leveraging the therapeutic potential of psilocybin.
This development marks a significant step for Red Light Holland in its journey towards global distribution and recognition in the psychedelic therapy space, showcasing the potential of naturally-sourced psilocybin in medical and therapeutic applications.
